2024 SABCS
Sherko Kuemmel, MD on Final Survival Results From the WSG ADAPT-HR+/HER2-Negative Chemotherapy Trial
Presented by Sherko Kuemmel, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium The WSG ADAPT trial in patients with HR-positive, HER2-negative breast cancer established that the ...
Komal Jhaveri, MD, FACP on The Phase III EMBER Trial
At the San Antonio Breast Cancer Symposium, Komal Jhaveri, MD, FACP, presented results of the phase III EMBER-3 trial of imlunestrant, an oral selective estrogen receptor degrader as monotherapy and c...
Jame Abraham, MD, FACP on the PATINA Trial
Presented by Otto Metzger, MD, on December 12, 2024, at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The phase III PATINA trial showed that the addition of palbo...
Jame Abraham, MD, FACP on the Phase III ZEST Trial
Presented by Nicholas Turner, MD, PhD, on December 13, 2024 at the San Antonio Breast Cancer Symposium Discussed here by Jame Abraham, MD, FACP The ZEST phase III clinical trial was designed to ev...
Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer
Andrew Tutt, MB ChB, PhD, FMedSci, Director of The Breast Cancer Now Toby Robins Research Centre and the Institute of Cancer Research (ICR) and Guy’s Hospital King’s College, London, discusses longer-...
Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer
Nan Chen, MD, of the University of Chicago Medicine, Chicago, discusses the impact of anthracyclines in high genomic risk node-negative HR-positive/HER2-negative breast cancer (Abstract GS3-03).
Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer
Adrienne Waks, MD, of Dana-Farber Cancer Institute, Boston, discusses the randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab vs paclitaxel/trastuzumab/pertuzumab in pat...
Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Aditya Bardia, MD, of UCLA David Geffen School of Medicine, Los Angeles, presents the additional analysis of the efficacy and safety of trastuzumab deruxtecan vs physician’s choice of chemotherapy by ...
Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE
Mafalda Oliveira, MD, PhD, of Vall d’Hebron Institute of Oncology, Spain, presented the primary results of SOLTI VALENTINE, a neoadjuvant randomized phase II trial of HER3-DXd alone or in combination ...
Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer
Sibylle Loibl, MD, PhD, of the German Breast Group, Neu-Isenburg, Germany, presented primary results of the randomized phase III PADMA trial comparing first-line endocrine therapy plus palbociclib vs ...
